Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

How to Manage, Treat Anemia of Inflammation in Patients with Rheumatic Disease

Ruth Jessen Hickman, MD  |  Issue: December 2017  |  December 17, 2017

Iron-deficiency anemia most commonly develops as a consequence of blood loss. This can happen due to a number of factors, including gastrointestinal malignancy or severe menstruation. Certain diseases that are more common in rheumatic patients also increase the risk of iron-deficiency anemia, like autoimmune gastritis, inflammatory bowel disease, celiac disease or Helicobacter pylori infection. Some drugs commonly used in rheumatic patients also put patients at increased risk of gastric bleeding, including non-steroidal anti-inflammatory drugs and glucocorticoids.1

Rheumatologists must also consider possible drug-induced anemias when evaluating their patients. Janus kinase inhibitors such as tofacitinib can dampen the effect of erythropoietin on cells, leading to a mild anemia. Immunosuppressant drugs such as methotrexate and azathioprine sometimes cause bone marrow failure and a megaloblastic anemia, and other drugs can cause aplastic anemia. Others such as non-steroidal anti-inflammatory drugs and proton pump inhibitors can also decrease erythropoiesis or erythrocyte half-life.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Various disease-associated mechanisms can induce anemia, distinct from anemia of inflammation itself. Systemic lupus erythematosus (SLE) can induce anemia from hemolysis, aplasia, pure red cell aplasia, myelofibrosis or thrombotic microangiopathy.6 Secondary kidney complications, such as in SLE or systemic sclerosis, can also cause anemia due to reduced production of erythropoietin.

Vitamin deficiency also plays a role in some patients. Inadequate dietary intake of B12 or folic acid can cause a megaloblastic anemia. Folic acid deficiency can also occur as a result of methotrexate therapy given without adequate folic acid supplementation.1 Evidence also suggests that vitamin D plays a role in iron regulation, and that deficiency can contribute to anemia in patients with rheumatoid arthritis.7

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

If clinicians simply assume anemia is due to disease inflammation, they can miss other important medical conditions.

Pathophysiology of Anemia of Inflammation

In anemia of inflammation, the pathophysiology of the underlying disease also leads to anemia. This is why treating the underlying condition often adequately treats the anemia as well. Anemia of inflammation usually induces a mild to moderate anemia that is normochromic and normocytic on peripheral blood smear.5

In recent years, researchers have come to understand the important role of the iron-regulatory hormone hepcidin in anemia of inflammation. Abnormally high levels of hepcidin are thought to play a large role in triggering the condition. Hepcidin production is induced by increasing plasma and hepatic iron concentrations, as well as certain inflammatory cytokines.5

Molecularly, hepcidin targets the only known cellular iron exporter, ferroportin, which is expressed on cell membranes in tissues that deliver iron to plasma. When hepcidin binds ferroportin, it causes ferroportin endocytosis and its subsequent destruction. This results in proportional reduction of iron export to the plasma. Hepcidin regulates the iron delivery to plasma from the macrophages that recycle old erythrocytes. It also regulates the delivery of iron from the duodenal enterocytes absorbing dietary iron, as well as from hepatocytes participating in iron storage. Thus, high hepcidin limits the absorption, remobilization and recycling of iron, resulting in reduced levels of plasma iron.5

Page: 1 2 3 4 5 6 7 8 | Single Page
Share: 

Filed under:Conditions Tagged with:anemiaCauseClinicalDiagnosisinflammationkidneymacrocytic anemiaManagementoutcomepathophysiologypatient careRheumatic Diseaserheumatologistrheumatologysystemic inflammatory syndromeTestTreatmentvitamin deficiency

Related Articles

    Macrophage Activation Syndrome

    December 1, 2010

    A review of diagnosis, treatment, and prognosis

    Rheuminations: Epigenetics May Help to Explain Why Some Get Rheumatic Disease

    March 1, 2013

    Recent research around genes and environmental stresses suggests outside influences can make lasting changes to the genome via epigenetic mechanisms

    Route of Iron Replacement Doesn’t Impact IBD Activity, Quality of Life

    February 20, 2016

    NEW YORK (Reuters Health)—The route of iron replacement therapy alters the gut microbiome and metabolomics in patients with inflammatory bowel disease (IBD), but the route is unrelated to disease activity and quality of life, according to a new study. “Crohn’s disease patients are extremely fragile to disturbances and one might speculate about consequences in long-term…

    Diagnosis: Myopathy

    July 1, 2009

    Presentation and evaluation of metabolic causes

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences